Abstract
Background:Cancer antigen (CA) 125 tumor-associated antigen is a high molecular glycoprotein used for follow-up of epithelial ovarian cancer. The test is often requested as a differential diagnosis in patients with pleural or peritoneal fluid. This study analyzes the prevalence of CA-125 increases in a population of patients attending a general hospital and discusses the possible clinical implications of increased levels.
Methods:On 4 different days, 380 CA-125 assays were performed in randomly selected patients attending our hospital. Serum CA-125 was measured with a commercial enzyme immunoassay, and clinical records were reviewed for assessment of clinical parameters.
Results:Sixty-one patients (16%) had increased CA-125. The pathologies of these patients were heart failure in 9 (14.7%), lung disease 11 (18%), hepatic cirrhosis in 7 (11.4%), malignant tumors in 9 (14.7%), intra-abdominal nonhepatic disease in 6 (10%), previous surgery in 17 (27.8%), and miscellaneous in 2 (3%). Effusions were seen in 34 patients (55.7%).
Conclusions:Our data confirm the variety of benign and malignant pathologies coursing with increased CA-125. Cardiovascular and chronic liver disease were the most frequent diagnoses in patients with increased CA-125; this supports the opinion that CA-125 lacks utility as a marker for malignancy. CA-125 could have a role in the follow-up of cardiovascular, hepatic, and tumoral diseases with serosal involvement.
Similar content being viewed by others
REFERENCES
Petignat P, Joris F, Obrist R. How CA-125 is used in routine clinical practice. Eur J Cancer 2000; 36: 1933–7.
Bast RC, Xu FJ, Barnhill A, et al. CA-125: the past and the future. Int J Biol Markers 1998; 13: 179–87.
Jiménez Lacave A, Allende Monclús M. Falsos negativos y positivos de los marcadores tumorales: sus limitaciones en la práctica clínica. Aplicaciones clínicas al CA-125. Rev Clin Esp 2001; 201: 715–7.
Buamah P. Benign condition associated with raised serum CA-125 concentration. J Surg Oncol 2000; 75: 264–5.
Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993; 1–2: 93–8.
Zeimet AG, Marth C, Offner FA, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996; 3: 384–9.
Zeimet AG, Offner FA, Marth C, et al. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997; 17: 3129–31.
Nagele H, Bahlo M, Klapdor R, et al. CA-125 and its relation to cardiac function. Am Heart J 1999; 137: 1044–9.
Ott K, Sendler A, Heidecke CD, et al. Bronchogenic cyst of the esophagus with high tumor marker levels—a case report and review of the literature. Dis Esophagus 1998; 11: 130–3.
Yilmaz A, Ece F, Bayramgurler B, et al. The value of CA-125 in the evaluation of tuberculosis activity. Respir Med 2001; 95: 666–9.
Bilgin T, Karabay A, Dolar E, et al. Peritoneal tuberculosis with pelvic abdominal mass, ascites and elevated CA-125 mimicking advanced ovarian carcinoma: a series of 10 cases. Int J Gynecol Cancer 2001; 11: 290–4.
Manidakis IG, Angelakis F, Sifakis S, et al. Genital tuberculosis can present as disseminated ovarian carcinoma with ascites and raised CA-125: case report. Gynecol Obstet Invest 2001; 51: 274–6.
Mas MR, Comert B, Saglamkaya U, et al. CA-125: a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. Dig Liver Dis 2000; 32: 595–7.
Kumar KS, Lee WM. Chylous ascites with marked elevation of CA-125 in cirrhosis. Am J Gastroenterol 2000; 95: 3313–4.
Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 199; 94: 1613–8.
Ahmed AS, Long M, Donaldson D. Lessons to be learned: a case study approach—ascites and elevated serum CA-125 due to a pancreatic carcinoma. A diagnostic dilemma. J R Soc Health 2000; 120: 47–51.
Sperti C, Pasquali C, Perasole A, et al. Macrocystic serous cystadenoma of the pancreas: clinicopathologic features in seven cases. Int J Pancreatol 2000; 28: 1–7.
Kammerer-Doak DN, Magrina JF, Nemiro JS, et al. Benign gynecological conditions associated with a CA-125 level >1,000 U/ml. A case report. J Reprod Med 1996; 41: 179–82.
Kashyap RJ. Extremely elevated serum CA-125 due to endometriosis. Aust N Z J Obstet Gynaecol 1999; 39: 269–70.
But I, Reljic M. The value of serum CA-125 for the management of tubo-ovarian abscesses. Wien Klin Wochenschr 2000; 112: 1044–8.
Migishima F, Jobo T, Hata H, et al. Uterine leiomyoma causing massive ascites and left pleural effusion with elevated CA-125: a case report. J Obstet Gynaecol Res 2000; 26: 283–7.
Tavmergen E, Sendag F, Goker EN, et al. Value of serum CA-125 concentrations as predictors of pregnancy in assisted reproduction cycles. Hum Reprod 2001; 16: 1129–34.
Rippe B, Simonsen O, Heimburger O, et al. A. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348–57.
Sessler R, Konyar H, Haasche G, et al. The haemodialysis patient with night sweats, ascites, and increased CA-125. Nephrol Dial Transplant 2001; 16: 175–7.
Ho-dac-Pannekeet MM, Hiralall JK, Struijk DJ, et al. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 1997; 13: 17–22.
Sari R, Camci C, Sevine A, et al. The effect of abdominal surgery on serum CA-125 levels. Clin Exp Obstet Gynecol 2000; 27: 244–5.
Epiney M, Bertossa C, Weil A, et al. CA-125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000; 15: 1261–5.
Lazzarino M, Orlandi E, Klersy C, et al. Serum CA-125 is of clinical value in the staging and follow-up of patients with non-Hodgkin’s lymphoma: correlation with tumor parameters and disease activity. Cancer 1998; 82: 576–82.
Chou SM, Anderson JS. Primary CNS malignant rhabdoid tumor (MRT): report of two cases and review of literature. Clin Neuropathol 1991; 10: 1–10.
Watanabe M, Kanda T, Takatama M, et al. An autopsy case of malignant lymphoma with a high serum CA 125 level occurring only in the brain and pericardium. J Med 1996; 27: 221–7.
Ohta H, Koyama R, Nagai T, et al. Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation. Int J Clin Oncol 2001; 6: 157–62.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miralles, C., Orea, M., España, P. et al. Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies. Ann Surg Oncol 10, 150–154 (2003). https://doi.org/10.1245/ASO.2003.05.015
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2003.05.015